Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
at www.tipranks.com (Mon, 6-Apr 1:15 PM)
Denali Regains DNL593 Rights After Takeda Collaboration Ends
at www.tipranks.com (Fri, 3-Apr 2:57 PM)
